Definium Reaffirms Panorama Results, With a 5.1-Point Difference on Anxiety Scale

Key Facts

In its quarterly report issued on November 9, Definium Therapeutics restated previously reported positive results from the Panorama trial, in which DT120 recorded a 5.1-point difference versus placebo on the HAM-A scale at Week 12. The company said in its filing with the U.S. Securities and Exchange Commission that the trial met its primary endpoint and all key secondary endpoints. Panorama results, from the drug’s second Phase 3 trial in generalized anxiety disorder, were announced in September 2026. The Voyage trial results were announced in August, while results from the Emerge depression trial were announced on June 22. The third-quarter data therefore presented these prior results, rather than announcing new clinical results on the report date.

In Panorama, the difference between DT120 and placebo was 5.1 points on the HAM-A scale at Week 12, with statistical significance reported in the filing at p<0.0001. Voyage, the earlier trial in generalized anxiety disorder, recorded a 5.4-point difference on the same scale at Week 12, with similar statistical significance. The comparison places both trials within the Phase 3 anxiety program, with each reporting a separate result. The company said improvement in both anxiety studies emerged early, with changes in symptoms observed from Day 2. It added that these changes persisted at subsequent measurement points during the core portion of both studies.

The Phase 3 anxiety trials comprise a 12-week core phase that is randomized, double-blind and placebo-controlled, according to the company’s filing. Eligible participants can then enter a 40-week open-label extension. In the first part of Panorama, the company said DT120 at a dose of 100 micrograms was generally well tolerated. The filing said there were no drug-related serious adverse events or signal of suicidality. Discontinuation rates were also similar across the 100-microgram dose group, the 50-microgram group and placebo, at 10.4%, 11.5% and 10.3%, respectively.

Research and development expenses rose to $46.1 million in the third quarter of 2026, compared with $31.0 million in the same period of 2025, an annual increase of 49%. General and administrative expenses totaled $26.1 million, versus $14.7 million a year earlier, up 78%. The company attributed part of the increase in administrative expenses to a $3.4 million rise in commercial preparation spending, alongside higher corporate affairs and personnel costs. The expenses reflect continued development of drug candidates and commercial preparation before reaching the marketing stage. The company said in its filing that it had generated no revenue and had not brought any of its drug candidates to market, and that continued research and development requires ongoing funding.

The company continues to enroll participants in Ascend, a Phase 3 depression trial, and is targeting enrollment of about 165 participants. Definium expects an initial readout of Part A data in 2027. On the regulatory front, the company said it is targeting a drug approval application filing in the first half of 2027. DFTX shares closed at $35.39 on November 9, 2026. Ascend results and the regulatory filing remain upcoming milestones for DT120, while company disclosures indicate that its development and marketing are not yet complete.